Search Results

You are looking at 1 - 10 of 49 items for :

Clear All
Open access

M P Schuijt, C G J Sweep, R van der Steen, A J Olthaar, N M M L Stikkelbroeck, H A Ross and A E van Herwaarden

://doi.org/10.1210/jcem.85.3.6453 ) 10 Sarlis NJ Weil SJ Nelson LM . Administration of metformin to a diabetic woman with extreme hyperandrogenemia of nontumoral origin: management of infertility and prevention of inadvertent masculinization of a female fetus

Open access

Milène Tetsi Nomigni, Sophie Ouzounian, Alice Benoit, Jacqueline Vadrot, Frédérique Tissier, Sylvie Renouf, Hervé Lefebvre, Sophie Christin-Maitre and Estelle Louiset

) , whereas in women of reproductive age, the great majority of adrenal oncocytomas are nonfunctional (21) . We report herein a very unusual case of hyperandrogenism, in a young woman presenting with an adrenocortical oncocytoma. We have investigated the

Open access

Monika Bilic, Huma Qamar, Akpevwe Onoyovwi, Jill Korsiak, Eszter Papp, Abdullah Al Mahmud, Rosanna Weksberg, Alison D Gernand, Jennifer Harrington and Daniel E Roth

. Results In total, 559 woman–infant pairs were included in the study. Baseline characteristics did not differ across supplementation groups ( Table 1 ). The main findings including adverse event rates were previously described ( 28 ). Table 1

Open access

Magaly Zappa, Olivia Hentic, Marie-Pierre Vullierme, Matthieu Lagadec, Maxime Ronot, Philippe Ruszniewski and Valérie Vilgrain

( Fig. 1 ). Intraobserver variability was assessed for one reader (MZ) by repeating the assessment of tumour burden in all patients six months later. Figure 1 (A) 57-year-old woman with liver metastases from an ileal neuroendocrine tumour. Liver

Open access

Alice S Ryan, John C McLenithan and Gretchen M Zietowski

little is known about lipoprotein and glucose metabolism in middle-aged and older woman with a prior history of GDM. We hypothesized that pre- and postmenopausal women who have a history of GDM would be more obese with lower aerobic fitness, have greater

Open access

Sanna Mustaniemi, Marja Vääräsmäki, Johan G Eriksson, Mika Gissler, Hannele Laivuori, Hilkka Ijäs, Aini Bloigu, Eero Kajantie and Laure Morin-Papunen

clarify whether the performance of an early OGTT is necessary for all pregnant women with PCOS regardless of their BMI. Second, we wanted to investigate the role of other shared risk factors for PCOS and GDM, such as overweight or obesity, the woman’s own

Open access

Joakim Crona, Alberto Delgado Verdugo, Dan Granberg, Staffan Welin, Peter Stålberg, Per Hellman and Peyman Björklund

negatives generated by NGS ( Supplementary Table 1 ). Figure 2 Detailed coverage at bases annotated for PCC susceptibility genes. Patient 1: SDHC variant of uncertain clinical significance A 61-year-old woman was investigated due to therapy

Open access

Yessica Agudelo-Zapata, Luis Miguel Maldonado-Acosta, Héctor Fabio Sandoval-Alzate, Natalia Elvira Poveda, María Fernanda Garcés, Jonathan Alexander Cortés-Vásquez, Andrés Felipe Linares-Vaca, Carlos Alejandro Mancera-Rodríguez, Shahar Alexandra Perea-Ariza, Karen Yuliana Ramírez-Iriarte, Camilo Andrés Castro-Saldarriaga, Juan Manuel Arteaga-Diaz, Roberto Franco-Vega, Edith Ángel-Müller, Arturo José Parada-Baños and Jorge E Caminos

4 h after 20 weeks of gestation (in a woman with previously normal blood pressure) and proteinuria >300 mg by collection of 24-h urine ( 8 ). Severity features include thrombocytopenia, impaired liver function, progressive renal insufficiency

Open access

Michelle Hadjiconstantinou, Hamidreza Mani, Naina Patel, Miles Levy, Melanie Davies, Kamlesh Khunti and Margaret Stone

gain) is just related to PCOS or whether it’s because of my thyroid.’ (Participant 10, age 45). One south Asian participant reported that she had at first considered her symptoms as normal for a woman from her background: ‘Tiredness, heavy periods

Open access

Malin Nylander, Signe Frøssing, Caroline Kistorp, Jens Faber and Sven O Skouby

secretary instructed the investigators as to which serial numbers to supply each woman with. The participants were randomized in a 2:1 ratio (liraglutide:placebo), as we believed that this would facilitate the recruitment to the study. Outcomes